当前在线人数344
移民专栏首页 -> 孙律师专栏 -> 文章
F1 博士生 29 篇引用文EB2NIW 2.5个月批准
作者:孙律师     发文时间: 2013年08月25日 08:24:54
Law Offices of Sun
12121 Wilshire Boulevard • Suite 600 • Los Angeles, CA &#
8226; 90025
Tel: (310) 481-6118* Fax: (310) 481-6117*Web: www.sunlawfirm.us
Contact: Alicesunlaw@gmail.com
Member of American Immigration Lawyers’ Association (1996-Present)




A Ph.D. candidate in the research field of the pathogenesis of Parkinson’s
disease received CIS EB2NIW Approval in 82 days without RFE!


Our law firm recently succeeded in helping an exceptional pharmacological
and biomedical researcher apply for a green card in the EB2NIW
classification and get his petition approved in 82 days.

The client is a PhD graduate student working for the research projects to
conduct pioneering research on mTOR signaling, Parkinson's disease, neuron
cell death, neuroprotection and neurodegeneration at one of the largest
health science universities in the U.S. He has a M.S. degree in
Pharmacology. We helped him prepare and file documents under the
immigration classification of EB2NIW.

The applicant’s research is focused on exploring and understanding the
mechanisms of pathogenesis of Parkinson’s disease (PD), identifying
possible therapeutic targets, and developing effective pharmacologic
treatment to slow or halt the progression of PD. We have argued that the
applicant has made original and novel research contributions to drug
development to treat Parkinson’s disease, anxiety, insomnia, and alcohol
tolerance with decreasing abuse liability by investigating mechanism of
action of neuroactive steroids. Additionally, he played a critical role and
made significant contributions to the research on investigating the role of
glycogen metabolism and tumor necrosis factor in the pathogenesis of
diabetes. The successful outcomes of his research provided and will
continue to provide new therapeutic approaches/targets for intervention and
treatment of PD or PD-related diseases.

The client’s research projects, which have been funded by the National
Institutes of Health (NIH), Public Health Service (PHS) and the Veteran
Affairs Office of Research & Development (VA), are directly linked to the
health care of the United States, particularly in the area of PD.
Parkinson’s disease (PD) is the most prevalent age-related
neurodegenerative movement disorder, affecting up to 1 million of American
people. Incidence and prevalence of PD are growing as the American
population ages. The combined direct and indirect cost of PD, including
treatment, social security payments and lost income from inability to work,
is estimated to be nearly $25 billion per year in the United States alone.
Cardinal symptoms of PD include rigidity, tremor, slow movement and postural
instability which are caused by loss of neurons that secrete dopamine in a
brain region called substantia nigra and accumulation of the protein alpha-
synuclein that is toxic to these neurons. Currently, the mechanisms
underlying pathogenesis of PD are still not clear. There is no curative
therapy for PD, because available therapeutics only ameliorates symptoms but
not dopaminergic neuron loss or alpha-synuclein accumulation. Thus, it is
very important and urgent to understand the mechanisms of pathogenesis of PD
, identify possible therapeutic targets and develop effective pharmacologic
treatment to slow or halt the progression of PD. His seminal work is
significant in helping to develop effective drugs for PD treatment, and
beneficial to the healthcare of the United States, because it will improve
the quality of life of nearly one million PD patients and is both
practically significant and directly linked to national interests in that
respect.

The applicant has published 6 scholarly papers in highly esteemed
professional journals, including Psychopharmacology and American Journal of
Physiology - Endocrinology and Metabolism, and provided 13 presentations at
national and international conferences. We have thoroughly documented his
supporting evidence, including copies of journal publications, conference
presentations, 29 citations of his papers, awards/honors, etc. Additionally
, we helped our client prepare six (6) expert opinion letters in the field
of his research.

After our meticulous preparation of his EB2NIW documents, we filed his
applications to CIS Texas Service Center. Notably, the EB2NIW application
prepared and filed by our law firm on May 8, 2013 was approved on July 29,
2013 without RFE.

The EB2NIW applicants who are outside the United States (e.g. in Korea) do
not need a U.S. employer to sponsor a green card application. The
applicant needs to have a U.S. institute provide a ‘Letter of Intent to
Offer’ to USCIS to prove that he/she will be offered a research position in
his/her field of specialty in the United States after obtaining a green
card.

Our law firm has substantial experience for more than 18 years to help
postdoctoral researchers, professors, engineers, and other advanced degree
professionals apply for nonimmigrant status in O1, H1B, etc., and green card
applications in EB1A, EB1B and EB2NIW. For more information, you can visit
our website at www.sunlawfirm.us

We provide Free Evaluation services. If you are interested in a Green Card
application, please email us your resume, the number of citations of your
works, and your main contributions to alicesunlaw@gmail.com. Subject: Green
Card Application.


Alice H. Sun (Member of American Immigration Lawyers Association)
Law Offices of Sun
12121 Wilshire Blvd., Suite 600
Los Angeles, CA 90025
Tel: (310) 481-6118
Fax: (310) 481-6117
alicesunlaw@gmail.com,
http://www.sunlawfirm.us.

Disclaimer: The above newsletter information is general information. They
are NOT legal consultations for any specific cases or legal issues.



[快速返回]
赞助链接
未名交友
将您的链接放在这儿
联系我们 - 服务条款 - 隐私权政策
版权所有 - 未名空间 - 中国大陆站(mitbbs.com.cn)- since 1996
京ICP备11000798号